You are here
EU Regler
The European training programme in Paediatric Haematology and Oncology
|
||||||||||||||||||||||||||||||||||||||||||||
 EUROPEAN BOARD OF PAEDIATRICS THE EUROPEAN TRAINING PAEDIATRIC HAEMATOLOGY AND This training document outlines one of the subspecialist training programmes in Tertiary Care Paediatrics, defined by the European Union of Medical Specialists (UEMS).  This programme has been drafted by the Education and Training Committee of the Société Internationale dâOncologie Pédiatrique Europe (SIOPE) and the European Society of Paediatric Haematology and Immunology (ESPHI).  Approval is sought from the European Board of Paediatrics (EBP) and the Confederation of European Societies of Paediatrics (CESP) which is the UEMSâs Section of Paediatrics. Jillian R Mann Education and Training Committee of SIOP Europe and ESPHI CONTENTÂ
MEMBERSHIP OF THE Professor Jillian R Mann (Chairman), Paediatric Oncology, UK Professor U Creutzig, Paediatric Haematology/Oncology, Dr FGH Hill, Paediatric Haematology, UK Professor W Kamps, Paediatric Haematology/Oncology, Dr G Perilongo, Paediatric Haematology/Oncology, Italy  Dr A Navajas, Paediatric Haematology and Oncology, Spain Dr K Schmiegelow, Paediatric Haematology/Oncology, Professor J-M Zucker, Paediatric Haematology/Oncology, France Professor F-M Fink, Paediatric Haematology/Oncology,  1. INTRODUCTION This document sets out the minimum requirements for training in Tertiary Care Paediatric Haematology and Oncology.  It defines the proposed European Training Programme for the education of specialists in Paediatric Haematology and Oncology who will practice their skills and expertise within the framework of a specialised tertiary care unit. Paediatric Haematology and Oncology are greatly overlapping specialties and in many countries such as North America and Australasia, as well as in many countries in Europe, they are regarded as one specialty.  Paediatric Haematology includes the care of children with leukaemia and non-malignant conditions such as coagulation disorders and haemoglobinopathies, and also children having bone marrow transplant.  In some European countries Paediatric Haematologists also run haematology laboratories, providing a diagnostic and consultative service for which they require additional training. This extra training is controlled by the relevant national body.  Paediatric Oncology incorporates the care of children with leukaemia, tumours of the central nervous system and with other solid tumours and may include the care of children having bone marrow transplants or other stem cell rescue procedures. In most specialised tertiary centres specialists in Paediatric Haematology and Oncology work as a team, providing mutual cross-cover, individual specialists in the bigger centres often having specific interests and responsibilities, for example in coagulation disorders, bone marrow transplant, leukaemia or CNS tumours. The suggested training programme has been designed in a modular fashion, the modules containing core knowledge and skills which are essential for all trainees in Paediatric Haematology and Oncology.  Guidance is given for the minimum training required in each module.  Trainees will be expected to spend additional time in certain modules, depending upon their final career intentions. It is recognised that Paediatric Haematology and Oncology are academic specialties with the majority of treatments for leukaemia and other cancers being managed within national or international clinical trials.  The management of many of the non-malignant disorders is often protocol-driven.  Complex laboratory investigations are necessary both for diagnosis and clinical management as well as for better understanding of the diseases.  Therefore, in addition to the minimum training described in this document, which should lead to the Certificate of Completion of Specialist Training (CCST), many trainees will choose to spend an extra period of several years undertaking laboratory or other research.  While such research training and experience are not considered in this document, all trainees will be expected to become familiar with research methodologies.Back 2. PAEDIATRIC TRAINING IN EUROPE The task of harmonising training programmes and training assessments through Europe lies within the remit of the European Board of Paediatrics (EBP) which has been specifically charged by CESP to undertake this task  To achieve this the EBP will recommend the standards for specialist training in paediatrics, including training quality, syllabus and minimal standards for training centres.  To this end recognition has been given to the diverse training needs of different types of Paediatrician and carefully constructed training programmes have been proposed. The EBP has designated the following training system: A)         Common Trunk â a three year training in basic The training programme described in this document relates to the 3 year programme in Tertiary Care Paediatrics, that is in Paediatric Haematology and Oncology.   Trainees will have completed their 3 years Common Trunk training in basic Paediatrics before starting their training in Paediatric Haematology and Oncology. Exceptionally trainees may enter the specialty from adult Medicine and Haematology; these trainees will need to undertake training in basic Paediatrics as well as training in Paediatric Haematology and Oncology. Back  3.        AIMS OF TRAINING On the basis of this training, European specialists in Paediatric Haematology and Oncology will acquire an understanding of children with blood disorders or cancer and will be clinically competent in their diagnosis and management.  The trainee will also have an understanding of the scientific principles of haematological disorders and childhood cancers and of the specialty related laboratory test procedures (including safety aspects), interpretation of the results and management aspects of their specialty.  The trainee is expected to be familiar with clinical skills (including risk benefit assessment), research methodologies, teaching and presentation methods, and ethical issues pertaining to research and clinical management.  This should include in?patient and out-patient care and the routine application of specialised diagnostic and therapeutic methods.  The specialist should understand the principles of clinical trials and obtaining consent, and be able to follow protocols and manage patients participating in them.  Experience in teaching should be provided during the specialist training.Back  4             TRAINING PROGRAMME  4.1.          Structure of Programme The programme is structured to recognise that on completion of training specialists in Paediatric Haematology and Oncology in Europe do not all carry the same range of responsibilities.  Many undertake the care of children with all types of non-malignant haematological disorder and also children with leukaemia, lymphoma, solid tumours and CNS tumours.  They may also do bone marrow/stem cell transplantation and may have limited laboratory duties such as the reporting of blood and bone marrow films.  In the larger centres some Paediatric Haematologists/Oncologists may specialise in, for example, leukaemia, neuro-oncology or transplantation while usually also carrying out other responsibilities in the speciality.  Some Haematologists have little or no responsibility for patients with malignancy, but specialise in non-malignant haematology and haemostasis. Each traineeâs progress is monitored by the training director (tutor) in the primary training centre, by the national training body and by the trainee him/herself.  The trainee should maintain a personal log book (portfolio) where relevant training experiences are recorded.  The traineeâs progress and portfolio are appraised with the trainee by the tutor at least every 6 months. Details of the methods for monitoring trainees and assessing their progress will be published elsewhere. For each EU Member State a list of centres, units, training directors (tutors) and other teachers should be compiled and updated on an annual basis.  A centre must have received accreditation for training and the training tutor (director) must have been practising Paediatric Haematology and Oncology for at least 5 years after the completion of his/her training.  When a training module cannot be provided by the centre, it must be taught elsewhere.  Neighbouring centres may collaborate in order to provide a complete training programme.  7.            NATIONAL TRAINING PROGRAMMES  7.1            EU Countries with Existing Programmes Each national syllabus should be scrutinised by the joint Education and Training Committee of SIOPE and ESPHI for compatibility.  If compatible the trainees successfully completing training within that programme would be eligible for a European title within Paediatric Haematology and Oncology. 7.2      EU Countries without Existing Programmes National professional bodies should be encouraged to adopt a national training programme in Paediatric Haematology and Oncology and to structure it in close compatibility with the European model.  This should be scrutinised by the SIOPE/ESPHI committee. Until implementation of such a national training programme, individuals should have the opportunity to train according to the European programme and to document their progress in a similar fashion.  Review of progress would be made by the EBP in conjunction with SIOPE and ESPHI. 7.3       Non-EU European Countries National professional bodies may wish to adopt a national training programme in Paediatric Haematology and Oncology and to structure it in close compatibility with the European model.  This can be scrutinised by the SIOPE/ESPHI committee. Until implementation of such a national training programme, individuals should have the opportunity to train according to the European programme. Back 8.          ASSESSMENT OF TRAINEES Most EU countries do not at present have an exit examination in Paediatric Haematology and Oncology.  It is considered premature to come to any final decision as to whether it will be desirable or feasible to establish an examination that would be acceptable to all the member states, though this may turn out to be the most objective way of establishing a uniform standard across Europe. In the short term it may be desirable for exit examinations to be introduced on a national basis, but in any case the Education and Training Committee of SIOPE/ESPHI will be making recommendations on assessment procedures. Back APPENDIX 1 MODULAR TRAINING PROGRAMME IN PAEDIATRIC HAEMATOLOGY/ONCOLOGY
Footnote for Appendix 1 The period shown for each module indicates the minimum proportion of the 3 year training programme that every trainee must spend in each.  The flexible period of 18 months will be spent preparing the trainee for his/her anticipated future career.  For example, trainees expecting to work mainly caring for children with malignant disease would spend most of this time caring for children with leukaemia, CNS and solid tumours, whereas those planning to work mainly in non-malignant haematology would spend the majority of the time increasing their experience in clinical and laboratory haematology ± leukaemia and bone marrow/stem cell transplant. Back APPENDIX 2 SYLLABUS FOR TRAINING IN PAEDIATRIC HAEMATOLOGY/ONCOLOGY Module 1 - Scientific Basis of Paediatric Haematology and Oncology Psycho-social aspects Module 2 - Generic Training in Practical Skills Required in Paediatric Haematology and Oncology Optimal use of diagnostic services Module 3 - Laboratory Haematology Blood transfusion Module 4 â Clinical non-malignant Paediatric Haematology Anaemias including nutritional Module 5 â Clinical Malignant Haematology, (Leukaemia, Lymphoma Myelodysplasia, MDS) Diagnosis, including cytology, morphology, cytogenetics and immunophenotyping (including being able to report the results) Module 6 - Bone Marrow Transplant/Stem Cell Transfusion (Clinical) Indications for transplant/stem cell transfusion Module 7 - CNS Tumours (Clinical) In conjunction with neuro-surgeon and radiotherapist, diagnosis, in- and out-patient care Module 8 - Solid Tumours Outside the CNS (Clinical) â including neuroblastoma, nephroblastoma, soft tissue and bone sarcomas, germ cell tumours, retinoblastoma, liver tumours, endocrine and epithelial tumours In conjunction with paediatric surgical oncologists and paediatric radiotherapists, diagnosis, in- and out-patient care Module 9 â Flexible This may include further experience in aspects of any of the other 8 modules (for example, in laboratory haematology, tumour molecular biology or the care of children with coagulation disorders, haemoglobinopathies, leukaemia, CNS or other solid tumours) or time in research.  This experience may be gained in the traineeâs country or abroad.  A three month period in immunology might be chosen by some trainees, to include neonatal immunology, immunodeficiency disorders, transplantation immunology and immunomodulation.  Research must be undertaken under expert supervision in which the trainee learns to plan, conduct, evaluate, publish and present research projects but not more than 6 months may be spent in full time research.   Experience abroad will only be acceptable when undertaken in an institution considered suitable by the national body responsible for overseeing training. |